Process to inhibit binding of the integrin &agr;4&bgr;1 , to VCAM-1 fibronectin and cyclic peptides thereof
US6713604B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | May 8, 1996 |
| Grant date | Mar 30, 2004 |
| Priority date | — |
| Expiry date | May 8, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of &agr;4&bgr;1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses &agr;4&bgr;1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.